Multi-drug resistant (MDR) oral Candida species isolated from HIV-positive patients in South Africa and Cameroon

Simple item page
dc.contributor.authorAbrantes, Pedro Miguel dos Santos
dc.contributor.authorMcArthur, Carole P.
dc.contributor.authorAfrica, Charlene W.J.
dc.date.accessioned2014-05-21T14:18:55Z
dc.date.available2014-05-21T14:18:55Z
dc.date.issued2014
dc.description.abstractCandida species are a common cause of infection in immune-compromised HIV-positive individuals, who are usually treated with the antifungal drug, fluconazole in public hospitals in Africa. However, information about the prevalence of drug resistance to fluconazole and other antifungal agents on Candida species is very limited. This study examined 128 Candida isolates from South Africa and 126 Cameroonian Candida isolates for determination of species prevalence and antifungal drug susceptibility. The isolates were characterized by growth on chromogenic and selective media and by their susceptibility to nine antifungal drugs tested using the TREKā„¢ YeastOne9 drug panel (Thermo Scientific). Eighty three percent (82.8%) of South African isolates were C. albicans (106 isolates), 9.4% were C. glabrata (12 isolates) and 7.8% were C. dubliniensis (10 isolates). Of the Cameroonian isolates, 73.02% were C. albicans (92 isolates); 19.05% C. glabrata (24 isolates); 3.2% C. tropicalis (4 isolates); 2.4% C. krusei (3 isolates); 1.59% either C. kefyr, C. parapsilopsis or C. lusitaneae (2 isolates); and 0.79% C. dubliniensis (1 isolate). Widespread C. albicans resistance to azoles was detected phenotypically in both populations. Differences in drug resistance were seen within C. glabrata found in both populations. Echinocandin drugs were more effective on isolates obtained from the Cameroon than in South Africa. A multiple drug resistant (MDR) C. dubliniensis strain isolated from the South African samples was inhibited only by 5-flucytosine in vitro on the YO9 panel. Drug resistance among oral Candida species is common among African HIV patients in these two countries. Regional surveillance of Candida species drug susceptibility should be undertaken to ensure effective treatment for HIV-positive patients.en_US
dc.description.accreditationWeb of Scienceen_US
dc.description.sponsorshipNational Research Foundation of South Africaen_US
dc.identifier.citationAbrantes, P.M.D.S. McArthur, C.P. &Africa, C.W.J. (2014). Multi-drug resistant (MDR) oral Candida species isolated from HIV-positive patients in South Africa and Cameroon. Diagnostic Microbiology and Infectious Disease, 79(2): 222ā€“227en_US
dc.identifier.issn0732-8893
dc.identifier.urihttp://hdl.handle.net/10566/1082
dc.language.isoenen_US
dc.privacy.showsubmitterfalse
dc.publisherElsevieren_US
dc.rightsĀ© 2014 Elsevier. This is the authors' final version and may be freely used provided that the source is acknowledged.
dc.source.urihttp://dx.doi.org/10.1016/j.diagmicrobio.2013.09.016
dc.status.ispeerreviewedtrue
dc.subjectCandidaen_US
dc.subjectDrug resistanceen_US
dc.subjectTREKen_US
dc.subjectAntifungal agentsen_US
dc.titleMulti-drug resistant (MDR) oral Candida species isolated from HIV-positive patients in South Africa and Cameroonen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AbrantesMulti-drugResistant2014.pdf
Size:
132.5 KB
Format:
Adobe Portable Document Format
Description:
Author final version
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.55 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Medical Bioscience)